Protalix BioTherapeutics (PLX) Total Current Liabilities (2010 - 2026)

Protalix BioTherapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $31.4 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 30.3% year-over-year to $31.4 million in Q2 2026; TTM through Jun 2026 was $31.4 million, a 30.3% increase from a year earlier, with the FY2025 full-year figure at $26.5 million, up 3.5% from the prior year.
• Total Current Liabilities was $31.4 million for Q2 2026 at Protalix BioTherapeutics, up from $27.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $58.0 million in Q2 2024, with the low at $21.9 million in Q3 2025.
• Average Total Current Liabilities over 5 years is $33.0 million, with a median of $31.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities plunged 67.83% in 2022, then jumped 150.86% in 2024.
• Over 5 years, Total Current Liabilities stood at $32.4 million in 2022, then surged by 40.4% to $45.5 million in 2023, then tumbled by 43.73% to $25.6 million in 2024, then grew by 3.5% to $26.5 million in 2025, then gained by 18.38% to $31.4 million in 2026.
• The last three Total Current Liabilities figures came in at $31.4 million (Q2 2026), $27.4 million (Q1 2026), and $26.5 million (Q4 2025), per Business Quant data.